Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Project Grant

University of Alberta

$757,350.00

Synthetic Biomaterials to Package and Deliver siRNA Nanoparticles in order to Curb Uncontrolled Growth of Leukemic Cells

FY 2020-21

Summary
Leukemias are a significant cause of death among cancer patients. Great strides have been made in understanding the factors causing leukemia and numerous new types of drugs are being continuously explored for therapy. However, the traditional chemotherapy is still the treatment of choice for most leukemias, but it is rarely curative and it loses its effectiveness on the long-term therapy. The main reason for this is that the leukemic cells adopt and become resistant to chemotherapy. This project is intended to develop a new approach for therapy of leukemia by developing a new type of drug for therapy. We plan to achieve this by silencing (or eradicating) the molecules responsible for uncontrolled growth of cancerous cells. Engineered biomaterials effective for silencing will be paramount to accomplish the desired goal. The biomaterials are intended to deliver the silencer molecules into leukemic cells without harming the healthy cells. Animal models will be utilized to determine the effectiveness of the proposed biomaterials. If successful, our approach will introduce a new treatment modality for leukemia.
Program
Project Grant
Location
Alberta, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
432963
Name
Uludag Hasan
Region
Alberta
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Cancer Research
Theme2
Biomedical
Prcname2
Biomedical Engineering
Projecttitle
Synthetic Biomaterials to Package and Deliver siRNA Nanoparticles in order to Curb Uncontrolled Growth of Leukemic Cells
Programtype2
Operating Grants
Orgnameinp2
University of Alberta
Cihramount2
$757,350
Cihrequipment2
$0
Programname2
Project Grant
Keyworddelim
Amphiphilic Polymers; Animal Model; Anti-Cancer Therapy; Drug Resistance; Leukemia; Molecular Therapy; Nanoparticles; Patient Derived Cells; Polymeric Biomaterials; Sirna Delivery
Abstract
Leukemias are a significant cause of death among cancer patients. Great strides have been made in understanding the factors causing leukemia and numerous new types of drugs are being continuously explored for therapy. However, the traditional chemotherapy is still the treatment of choice for most leukemias, but it is rarely curative and it loses its effectiveness on the long-term therapy. The main reason for this is that the leukemic cells adopt and become resistant to chemotherapy. This project is intended to develop a new approach for therapy of leukemia by developing a new type of drug for therapy. We plan to achieve this by silencing (or eradicating) the molecules responsible for uncontrolled growth of cancerous cells. Engineered biomaterials effective for silencing will be paramount to accomplish the desired goal. The biomaterials are intended to deliver the silencer molecules into leukemic cells without harming the healthy cells. Animal models will be utilized to determine the effectiveness of the proposed biomaterials. If successful, our approach will introduce a new treatment modality for leukemia.
Competitiondate
202010
Approvedterm2
5 yrs 0 mth
Pinamesdelim
Uludag, Hasan
Approvedterm
5 ans 0 mois
Cihrcontribution2
~ $757,350~ $0~
University of Alberta - $757,350 Grant (2020-21) | Canada Spends